HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6- fluoro- 9- methyl- 2- phenyl- 4- (pyrrolidin- 1- yl- carbonyl)- 2,9- dihydro- 1H- pyrido(3,4- b)indol- 1- one

structure in first source

Also Known As:

SL65.1498; SL651498

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - 6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyrido(3,4-b)indol-1-one: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyrido(3,4-b)indol-1-one: 3

Experts

1.	Griebel, Guy: 2 articles (06/2005 - 01/2003)
2.	Cook, James M: 1 article (06/2005)
3.	Licata, Stephanie C: 1 article (06/2005)
4.	Platt, Donna M: 1 article (06/2005)
5.	Rowlett, James K: 1 article (06/2005)
6.	Sarma, P V V Srirama: 1 article (06/2005)
7.	Avenet, Patrick: 1 article (01/2003)
8.	Cohen, Caroline: 1 article (01/2003)
9.	Depoortere, Henri: 1 article (01/2003)
10.	Evanno, Yannick: 1 article (01/2003)

Related Diseases

1.	Ataxia (Dyssynergia) 06/01/2005 - "In addition, SL651498 fully induced muscle relaxation, but unlike conventional BZs, engendered minimal ataxia. " 01/01/2003 - "However, unlike these latter drugs, SL651498 induced muscle weakness, ataxia or sedation at doses much higher than those having anxiolytic-like activity (MED: 30 to 100 mg/kg, i.p. " 08/01/2001 - "Results from activity tests and electroencephalogram analysis indicated that SL651498 induced muscle weakness, ataxia, or sedation at doses much higher than those producing anxiolytic-like activity (MED > or = 30 mg/kg, i.p.). "
2.	Muscle Weakness 01/01/2003 - "However, unlike these latter drugs, SL651498 induced muscle weakness, ataxia or sedation at doses much higher than those having anxiolytic-like activity (MED: 30 to 100 mg/kg, i.p. " 08/01/2001 - "Results from activity tests and electroencephalogram analysis indicated that SL651498 induced muscle weakness, ataxia, or sedation at doses much higher than those producing anxiolytic-like activity (MED > or = 30 mg/kg, i.p.). "
3.	Spasm (Spasms) 01/01/2003 - "SL651498 represents a promising alternative to agents currently used for the treatment of anxiety disorders and muscle spasms without the major side effects seen with classical BZs." 01/01/2003 - "SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms." 01/01/2003 - "SL651498 (6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyrido[3,4-b]indol-1-one) was identified as a drug development candidate from a research program designed to discover subtype-selective GABA(A) receptor agonists for the treatment of generalized anxiety disorder and muscle spasms. "
4.	Anxiety Disorders (Anxiety Disorder) 01/01/2003 - "SL651498 represents a promising alternative to agents currently used for the treatment of anxiety disorders and muscle spasms without the major side effects seen with classical BZs." 01/01/2003 - "SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms." 01/01/2003 - "SL651498 (6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyrido[3,4-b]indol-1-one) was identified as a drug development candidate from a research program designed to discover subtype-selective GABA(A) receptor agonists for the treatment of generalized anxiety disorder and muscle spasms. "

Related Drugs and Biologics

1.	Anti-Anxiety Agents (Anxiolytics)
2.	GABA-A Receptor Agonists